Kenya is among eight African countries that participated in clinical trials for a newly approved malaria treatment, specifically designed for newborns.
Other participants, include Nigeria, the Democratic Republic of Congo, Burkina Faso, Mali, and Zambia.
The medicine, Coartem Baby (artemether‑lumefantrine), was approved by Swissmedic, Switzerland's regulatory authority.
This marks a significant milestone in the fight against malaria in infants, as it becomes the first treatment developed for use in newborns.
